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Abstract 1 
Background 2 
Few studies have quantified the incidence and prevalence of coeliac disease (CD) and dermatitis 3 
herpetiformis (DH) nationally and regionally by time and age groups.  Understanding this 4 
epidemiology is crucial for hypothesising about causes and quantifying the burden of disease. 5 
Methods 6 
Patients with CD or DH were identified in the Clinical Practice Research Datalink between 1990 and 7 
2011. Incidence rates and prevalence were calculated by age, sex, year and region of residence. 8 
Incidence rate ratios (IRR) adjusted for age, sex and region were calculated with Poisson regression. 9 
Results 10 
9087 incident cases of CD and 809 incident cases of DH were identified. Between 1990 and 2011 the 11 
incidence rate of coeliac disease increased from 5.2/100,000 (95% CI, 3.8-6.8) to 19.1/100,000 (17.8-12 
20.5) (IRR 3.6, 95% CI 2.7-4.8). The incidence of DH decreased over the same time period from 13 
1.8/100,000 to 0.8/100,000 (average annual IRR 0.96, 95% CI 0.94-0.97). The absolute incidence of CD 14 
per 100,000 person years ranged from 22.3 in Northern Ireland to 10 in London. There were large 15 
regional variations in prevalence for CD but not DH. 16 
Conclusions 17 
We found a 4-fold increase in the incidence of CD in the UK over 22 years with large regional 18 
variations in prevalence. This contrasted with a 4% annual decrease in the incidence of DH with 19 
minimal regional variations in prevalence. These contrasts could reflect differences in diagnosis 20 
between CD (serological diagnosis and case finding) and DH (symptomatic presentation) or the 21 
possibility that diagnosing and treating CD prevents development of DH. 22 
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STUDY HIGHLIGHTS: 3 
WHAT IS CURRENT KNOWLEDGE 4 
x Coeliac disease incidence appears to be rising worldwide and in Finland the incidence of DH 5 
appears to be decreasing. 6 
x Variation by age, sex, time and geography in the UK in the incidence of coeliac disease and 7 
dermatitis herpetiformis is not well documented. 8 
 9 
WHAT IS NEW HERE 10 
Coeliac disease incidence has increased in the UK over the last 20 years in all age groups except those 11 
less than 5 years of age. 12 
Dermatitis herpetiformis incidence has decreased over the last 20 years in all age groups. 13 
There is variation in the rates of diagnosis of coeliac disease but not dermatitis herpetiformis 14 
throughout the UK suggesting opportunities for better ascertainment could be implemented. 15 
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Introduction 1 
Population based estimates of the incidence and prevalence of a disease are crucial for investigating 2 
the possible reasons for its occurrence and any changes in its underlying risk factors, but perhaps 3 
more importantly to quantify the likely burden upon health care systems and society in general
1
.  For 4 
coeliac disease (CD) numerous studies have been able to quantify the seroprevalence of positive 5 
anti-endomysial antibodies and/or anti-tissue transglutaminase antibodies in single populations and 6 
at single points in time
2
.  With some variation, the overall seroprevalence has been surprisingly 7 
constant at around 1% in most populations studied
3
.  This has not been the same for clinically 8 
recognised and diagnosed disease where disparities exist across time, place and individual 9 
characteristics, which indicates that there are opportunities for improving diagnostic pathways and 10 
health outcomes
4-9
.   11 
While many epidemiological studies on the incidence and prevalence of clinically diagnosed CD have 12 
been carried out relatively few have spanned long periods of time, in the same population and 13 
studied both CD and dermatitis herpetiformis (DH) together
9
.  Those that have been published
10-15
 14 
are very small, have not included all age groups
16
, are neither population based nor nationwide 15 
(having focussed on for example only US military personnel
17
 or specific regions of a country
4 18
) and 16 
have used variable disease definitions
19
.  Some incidence studies among children have shown a 2 to 17 
3-fold increase in incidence of CD in Denmark and Sweden over a 13 year period
5 8
 and another study 18 
in Scotland has shown a 6-fold increase over 20 years
20
, but no general population based longitudinal 19 
data (over multiple decades) are available for all regions of a nation for adult CD.  Similar information 20 
for dermatitis herpetiformis (DH) is not so readily available but that which is mainly comes from 21 
Finland and suggests that DH is becoming less common
21 22
.  This reduction is in direct contrast to CD
4 
22 
14
, and would be a surprising result if confirmed, as both CD and DH are thought to share underlying 23 
pathophysiology.  However, one intriguing possible explanation of such divergent trends might be 24 
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that less exposure to gluten following a diagnosis of CD prevents DH from developing as originally 1 
proposed by Salmi et al
22
. 2 
To quantify the incidence and prevalence of clinically diagnosed CD and DH and make comparisons 3 
with the known seroprevalence we carried out a large population based study across all regions of 4 
the UK using routinely available electronic medical data.  We have therefore been able to determine 5 
variations in incidence and prevalence by age, sex, geographical region and calendar time over a 22 6 
year period. 7 
 8 
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Methods 1 
Study population 2 
Data were extracted from the Clinical Practice Research Datalink (CPRD) (version July 2012) accessed 3 
ƵŶĚĞƌƚŚĞhŶŝǀĞƌƐŝƚǇŽĨEŽƚƚŝŶŐŚĂŵ ?ƐWZůŝĐĞŶƐĞ ?dŚĞƐĚĂƚĂĐŽŶtain electronic information on 4 
consultations, diagnoses and prescriptions delivered in primary care in the UK, and have been 5 
validated for a wide variety of diagnoses
23
.  The accuracy of the diagnosis of CD in CPRD has also 6 
been specifically validated against medical records obtained previously for a sample of individuals 7 
and shown to be good
24
. For this study we used patients who were registered at a practice at some 8 
point from 1
st
 January 1990 to 31
st
 December 2011 inclusive.  This dataset contains approximately 57 9 
million person years of available data for analysis among 12 million contributing patients within 644 10 
general practices and is generally representative of the population of the United Kingdom.  Within 11 
ƚŚĞĚĂƚĂƐĞƚ ?ƉĂƚŝĞŶƚƐĂƌĞůĂďĞůůĞĚĂƐ ‘ĂĐĐĞƉƚĂďůĞ ?ĨŽƌƵƐĞŝŶƌĞƐĞĂƌĐŚ ?ĂŶĚĚĂƚĂƌĞĐŽƌĚĞĚĚŽŶŽƚƌĂŝƐĞ12 
concerns about validity and are recorded to the high research standard defined by CPRD.  For this 13 
ƐƚƵĚǇǁĞŽŶůǇƵƐĞĚ ‘ĂĐĐĞƉƚĂďůĞ ?ƉĂƚŝĞŶƚƐ.  This study was approved by the Independent Scientific 14 
Advisory Committee of the CPRD (protocol 12_106R).   15 
We identified people with Read codes
25
 representing CD (J690.00 Coeliac Disease; J690.13 Gluten 16 
enteropathy; J690z00 Coeliac disease NOS; J690100 Acquired coeliac disease; J690.14 Sprue-17 
nontropical; J690000 Congenital coeliac disease) or DH (M140.00 Dermatitis herpetiformis; M145200 18 
Senile dermatitis herpetiformis; M142.00 Juvenile dermatitis herpetiformis).   Patients could have a 19 
diagnosis of both CD and DH.  The incidence and prevalence for each diagnosis was calculated 20 
separately as described below.  The date of the earliest recorded code for CD or DH was considered 21 
as the date of diagnosis for each case patient.   22 
Cases were classed as incident if their first code representing CD or DH occurred at least 12 months 23 
ĂĨƚĞƌƚŚĞƉĂƚŝĞŶƚ ?ƐĚĂƚĞŽĨƌĞŐŝƐƚƌĂƚŝŽŶǁŝƚŚƚŚĞ'WĂŶĚĂĨƚĞƌƚŚĞĨŝƌƐƚĚĂƚĞŽĨƵƉ-to-standard data for 24 
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the general practice.  All other cases were considered prevalent.  The methodology underpinning 1 
these definitions are described in full elsewhere
24
, have been used in other studies of CD using these 2 
data
26
 and of incidence of other chronic gastrointestinal diseases i.e. inflammatory bowel disease
27 28
.  3 
Statistical analysis 4 
We calculated crude incidence of CD and DH by dividing the number of newly diagnosed cases of 5 
each disease by the total follow-up time in the study period (1990-2011).  We stratified disease 6 
incidence by sex, age group (categorised a priori as 0-4 years, 5-17, 18-29, 30-49, 50-69 years, and 70 7 
years and over), calendar year, socioeconomic status of the area in which the general practice resides 8 
at which the patient was registered (quintiles by rank of Indices of Multiple Deprivation), and region 9 
of residence (defined based on location of the practice as either one of the 10 regions of England 10 
mapping to the government offices of the regions, or the other countries forming the UK: Wales, 11 
Scotland or Northern Ireland). The age categories were selected a priori, and children were separated 12 
into under 5 years and 5  ? 18 years as previous literature has shown an peak in incidence for under 5 13 
year olds.  Incidence rates were presented per 100,000 person years with a Poisson model fitted to 14 
determine incidence rate ratios (IRR).  These IRRs were fully adjusted for sex, age group, calendar 15 
year and region of residence.  Likelihood ratio tests were used to test for departure from linear trend 16 
for calendar year. 17 
Point prevalence of CD or DH was calculated for the 30
th
 of June 2011, using all cases (both incident 18 
and prevalent) that were diagnosed before or on this date and still alive and registered with a 19 
participating practice.  We then divided by the total CPRD population for acceptable registered 20 
patients at that date and calculated a percentage of the population with either CD or DH, and the 21 
respective 95% confidence intervals.   We then applied our prevalence and incidence results to the 22 
estimated general population in the UK to predict the current numbers living with CD and DH (and 23 
newly diagnosed) in 2011 in the whole of the UK based on our findings.   24 
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Subgroup Analyses 1 
We examined the trends in the incidence of CD in a number of subgroups. First we identified all 2 
patients who also had a diagnosis of another autoimmune disorder such as type 1 diabetes or thyroid 3 
disease. Secondly we identified patients with symptoms of weight loss or diarrhoea, or had a 4 
diagnosis of anaemia in the year before diagnosis. Finally we identified all patients who had an 5 
endoscopy within a year of diagnosis. For this latter analysis we restricted the population to those 6 
patients who had linked data from Hospital Episodes Statistics available (2000  ? 2010). 7 
Sensitivity analyses 8 
For the first sensitivity analysis we repeated all our analyses restricting our case populations to those 9 
who in addition to one diagnostic record of either CD or DH had a relevant prescription for a gluten-10 
free product and/or dapsone and/or a second documented record of their disease. As a second 11 
sensitivity analysis just for DH we broadened the case definition to include CD patients as additional 12 
DH patients if they were found to have a prescription for dapsone (but without a DH diagnostic 13 
code). 14 
Stata version 12 was used for all statistical analyses.   15 
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Results 1 
A total of 9087 incident cases of CD and 809 incident cases of DH were identified between 1990 and 2 
2011 equating to an overall incidence rate of 13.8 per 100,000 person years for CD and 1.2 per 3 
100,000 person years for DH.  There were 220 cases with an incident diagnosis of both DH and CD 4 
during the study period equating to an incidence of 0.3 per 100,000 person years. 5 
Incidence of coeliac disease 6 
Stratified incidence rates of CD by sex, age group, calendar year, socioeconomic status, and region of 7 
residence are displayed in table 1.  Incidence of CD was nearly twice as high in females as in males; 8 
adjusted IRR 1.85 (95%CI [1.78, 1.94]).  Incidence of CD by age showed a typical bimodal distribution 9 
with incidence rates highest in people less than 5 years of age and aged between 50-69 years (Table 10 
1).  Incidence increased overall across the 22 year period studied from 5.2 to 19.1 per 100,000 11 
person years (trend IRR 1.06 (1.05 - 1.06), p < 0.0001 adjusted for age, gender, region, and 12 
socioeconomic status), but this masked a significant interaction with age (likelihood ratio test 13 
p<0.0001) (Figure 1).  Incidence in the under 5 year old group remained relatively constant across the 14 
period studied; IRR 1.01(95%CI [0.99,1.03], p < 0.0001) (linear model for year adjusted for sex and 15 
region).  Incidence in 5-17 year olds increased annually by almost 10% each year; 5-17 year olds 16 
adjusted IRR 1.09, 95%CI 1.08-1.11, p < 0.0001) and 18-29 year olds adjusted IRR 1.09 (95%CI 1.07-17 
1.10, p < 0.0001). Incidence in those aged 30 and over increased more moderately at approximately 18 
4-7% a year.  There was marked regional variation in incidence with a significantly higher incidence 19 
seen in Northern Ireland (absolute incidence 22.3 per 100,000 person years) (Figure 2).   The lowest 20 
incidence was reported in the London region (absolute incidence 10 per 100,000 person years).  21 
Coeliac disease incidence was also higher among patients registered at general practices located in 22 
less socioeconomically deprived areas. 23 
Incidence of dermatitis herpetiformis 24 
Incidence and prevalence of CD and DH Page 11 
 
Stratified incidence rates of dermatitis herpetiformis by sex, age group, calendar year and region of 1 
residence are displayed in table 2.  Incidence of DH was almost identical in males and females; 2 
adjusted IRR 0.99 (95%CI [0.87, 1.14]).  Incidence of DH by age did not show as distinct a bimodal 3 
distribution as did CD though incidence in those aged under 5 was greater than those aged between 4 
5 and 29 years (Table 2). Incidence was highest in those aged 50-69 as in coeliac disease.  Incidence 5 
decreased overall across the 22 year period studied from 1.82 to 0.80 per 100,000 person years 6 
(Figure 3), representing a -4% change in incidence per year (IRR adjusted for sex, age group and 7 
region and socioeconomic status, 0.96 (95%CI [0.94, 0.97], p < 0.0001; there was no significant 8 
interaction between age and year (likelihood ratio test p=0.3562)).  There was however modest 9 
regional variation in incidence with absolute rates being highest in the Yorkshire & the Humber 10 
region (Figure 4).  There was no clear pattern of DH incidence by socioeconomic quintile. 11 
Prevalence of coeliac disease and dermatitis herpetiformis 12 
At 30th June 2011 there were 10,872 people with CD alive and contributing data which corresponded 13 
to a point prevalence of 0.24% across the entire population or 1 in every 420 people.  The prevalence 14 
was substantially higher in females than males and increased with increasing age.  The prevalence of 15 
DH was much lower at 0.03% (n=1160) across the entire population or 1 in every 3300 people. On 16 
30th June 2011 411 people had a diagnosis of both DH and CD (prevalence = 0.01%). 17 
Our dataset covers approximately 6% of the English population.  Based on our prevalence rates this 18 
equates to approximately 150,000 people living with CD and approximately 19,000 people living with 19 
dermatitis herpetiformis in the UK in 2011. Based on our incidence rates we estimate that 20 
approximately 12,000 of those with CD and 500 with DH had been newly diagnosed in that year. 21 
Subgroup analyses 22 
First, we examined the trends in incidence of CD with an autoimmune disease of either type 1 23 
diabetes or thyroid disease. The prevalence of a diagnosis of either type 1 diabetes or thyroid disease 24 
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among those with CD was around 0.9% and 1.3% respectively. The increase in the incidence of CD 1 
with either of these co-morbidities (trend IRR 1.06 (1.05 - 1.07), p < 0.0001) was unchanged from 2 
that of CD overall (IRR 1.06 (1.05 - 1.06), p < 0.0001) (both estimates adjusted for age, gender, region, 3 
and socioeconomic status). 4 
Second, the proportion of CD patients who had symptoms of weight loss or diarrhoea recorded in the 5 
previous year doubled over the study period from 25% to 51%. The increase in the incidence of this 6 
sub group (adjusted trend IRR 1.10 (1.09 - 1.11), p < 0.0001) was greater than that for CD overall. 7 
There was a similar increase in the proportion (from 18% to 53%) and the incidence of CD with 8 
anaemia recorded in the year prior to diagnosis (adjusted trend IRR 1.13 (1.12 - 1.13), p < 0.0001).  9 
 10 
Third, we identified any recording of a gastroscopy within a year of diagnosis for the subset of cases 11 
from primary care practices linked to HES between 2000 and 2010 (63% of English practices). The 12 
proportion of CD diagnoses with a recorded endoscopy increased from 63% to 72%, and after 13 
adjusting for age, gender, region, and socioeconomic status the trend persisted (trend IRR 1.11 (1.10 14 
- 1.12), p < 0.0001). 15 
Sensitivity analyses 16 
The results for incidence overall stratified by year when we restricted our CD case population to only 17 
those individuals with a gluten free or dapsone prescription or more than one diagnostic code are 18 
shown in figure 5.  These indicate that there was a 17% reduction in our estimated CD prevalence 19 
and 23% reduction in our CD incidence rates using this method.  This reduction in the estimates did 20 
not vary greatly by age at diagnosis, but did increase each year and varied by region in a similar way 21 
to the overall trends of CD for the full study.  For example the reduction in incidence varied by year 22 
from 14% in 1990 to 20% in 2010, and there was considerable variation by region, from 13% in 23 
Yorkshire and Humber to 34% in London. However despite this the overall trend in the increase of CD 24 
Incidence and prevalence of CD and DH Page 13 
 
incidence persisted (trend IRR 1.05 (1.04  ? 1.05), p < 0.0001, adjusted for age, gender, region, and 1 
socioeconomic status). 2 
The results for incidence overall stratified by year when we restricted our DH case population to only 3 
those individuals with a dapsone prescription or more than one diagnostic code, or broadened the 4 
DH case population to include CD with a dapsone prescription are shown in figure 6.  These indicate 5 
that broadly there was a 30-40% reduction in our estimated DH prevalence and incidence rates using 6 
the restricted population.  However even within this sensitivity analysis the overall trend in the 7 
decrease of DH incidence persisted (trend IRR 0.96 (0.94  ? 0.97), p < 0.0001, adjusted for age, gender, 8 
region, and socioeconomic status). 9 
 10 
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Discussion 1 
We found that across the 22 year period of our study there was a near 4-fold increase in the 2 
incidence of CD in the UK which contrasted starkly with a 4% annual decrease in the incidence of DH.   3 
We observed some regional variation in both diseases across the UK with Northern Ireland and 4 
Yorkshire & the Humber having the highest incidence rates of CD and DH respectively and noted that 5 
CD occurred more commonly among areas with least socioeconomic deprivation.  Our figures for 6 
prevalence estimate that about 3 in 10,000 children under 5 currently in the UK have diagnosed CD 7 
with this figure increasing to 4 in 1,000 adults over the age of 70.  For DH the prevalence estimates 8 
are approximately 10-fold lower.  On the basis of our incidence figures we estimate that in 2011 9 
approximately 12,000 people were newly diagnosed with CD and 500 with DH in the UK.   10 
Our study is the largest population based study of the occurrence of both CD and DH to date 11 
providing accurate incidence and prevalence rates for all ages and across a longer calendar period 12 
than has previously been reported.   Key to any measure of incidence is the method of defining the 13 
cases being counted as new diagnoses.  In this study we have defined a new case when an 14 
ŝŶĚŝǀŝĚƵĂů ?ƐŐĞŶĞƌĂů practitioner (GP) records a first diagnosis of either CD or DH in their medical 15 
record.  Such diagnoses in the UK are not made without a referral to secondary care and the 16 
diagnostic investigations inherent within that process
29-32
.  We believe this assumption is valid as 17 
previously we have investigated the accuracy of the diagnosis of CD recorded electronically by GPs, 18 
by reviewing the medical paper records including correspondence and results that emanated from 19 
secondary care
24
.  The agreement was improved in that validation study24 by insisting, within a more 20 
restrictive case definition, on each individual having a prescription for a gluten-free product or a 21 
second record of their disease. This case definition increased the specificity; a positive predictive 22 
value for a single code was 81%, a gluten free prescription was 89%, and two diagnostic codes was 23 
100%.  However this had the disadvantage of reducing the sensitivity of our case definition. We 24 
therefore used a single diagnostic code to maximise the sensitivity in the main analysis of our current 25 
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study and used the more specific definition in the sensitivity analysis. We found that 80% of coeliac 1 
patients had a prescription for a gluten free product or multiple codes which was entirely consistent 2 
with external data in previously published surveys of local regions and populations. First, Hall et al33 3 
conducted a questionnaire study of a sample of CD patients identified by Read codes in north east 4 
England, and reported that only 86% received a gluten free prescription. Additionally only 3% of 5 
those identified who returned the questionnaire stated that they did not have CD which provides 6 
additional evidence to support our use of Read codes in defining CD ?&ƵƌƚŚĞƌŵŽƌĞŽĞůŝĂĐh< ?Ɛ7 
commercial team surveyed their own members in 2012 and found that only 75% of members were 8 
using gluten free prescriptions (Coeliac UK (2012) Prescriptions Report), and in May 2013 a repeat 9 
survey in Oxford found that 80% of their members used gluten free prescriptions (Coeliac UK (2013) 10 
/ŵƉĂĐƚKǆĨŽƌĚƐŚŝƌĞZĞƉŽƌƚ ? ?KƵƌƐƚƵĚǇ ?ƐĨŝŶĚŝŶŐĨŽƌƚŚĞǁŚŽůĞŽĨƚŚĞh<ƚŚĂƚĂďŽƵƚ ? ?йŽĨCD 11 
patients are having a gluten free prescription is therefore what would be expected. 12 
 13 
It is possible that we would have underestimated our DH incidence rates if doctors have not recorded 14 
this additional diagnosis in people with CD as well.  We assessed this potential bias by including CD 15 
patients with a dapsone prescription (but no diagnostic record of DH) in our sensitivity analysis. The 16 
incidence rates for DH when we did this however remained broadly similar to those from comparable 17 
studies so we think it unlikely to have introduced a large bias. 18 
When trying to assess the incidence or prevalence of any chronic disease such as CD or DH it is not 19 
possible to identify the moment of biological onset but rather the date of acquisition of a diagnosis.   20 
Our definition of incidence relies on the fact that a general practitioner will record the diagnosis of a 21 
new disease at the time the diagnosis is made i.e. representing the real world of clinical practice.  22 
Measuring the incidence and prevalence of a disease requires an unbiased, general population based 23 
sample from which the cases can arise and be counted.  In that regard we are fortunate that the 24 
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CPRD is broadly speaking representative of the UK population as whole.  The only group of people 1 
that seems to be underrepresented in our population are those aged 18-25 which may be because 2 
people in this age group are more mobile
34
.  This could have led to an over estimate of the 3 
occurrence of disease in this age group in our study if those with disease are motivated to remain 4 
actively registered with a GP, regardless of their location, and are counted therefore in the numerator 5 
in contrast to individuals in that age group who are healthy and may not register with a GP on 6 
relocation and therefore not appear in the denominator. 7 
Prior studies on the incidence and prevalence of clinically diagnosed CD and DH in the general 8 
population that are comparable to our own are scarce
9
 and all have a smaller sample size.  Most 9 
studies have focussed on either CD or DH separately rather than describing the occurrence of both 10 
diseases drawn from the same population, or they have focussed on either children or adults or have 11 
reported only incidence or prevalence.   Four population based studies from Sweden
8
, Denmark
5
 and 12 
Scotland, UK
6 20
 have measured the incidence of CD in children using information from the whole of 13 
these nations.  In Swedish children under the age of 15 the reported annual rates increased from 19 14 
 ? 44 per 100,000 over the period 1998 to 2003 for the whole country.  The authors speculate that 15 
this particularly high rate was a consequence of high gluten consumption.  By contrast in Denmark 16 
the rates among children under the age of 18 ranged from 2.8 - 12.3 per 100,000 1999 to 2008.  In 17 
Scotland the annual age- and sex-standardised incidence rate reported for children under the age of 18 
16 between 2009 and 2010 was 10 per 100,0006.  When we also restricted our population to only 19 
Scottish practices, 2009 to 2010, under the age of 16 we found comparable rate of 12.3 (95% CI 8.5-20 
17.3) per 100,000.  Of the previously published studies only the Danish one quantified prevalence 21 
reporting that in 2010 this was 84 per 100,000 or 0.08%, which was similar to our own equivalent 22 
finding of 90/100,000 (prevalence in <18 year olds on 1
st
 January 2010).   23 
Our trends over time in adult CD diagnosis rates and prevalence were similar to three regional 24 
studies; two from the UK
18 35 36
 and one in the USA
27
. First the numbers of diagnoses made and rates 25 
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calculated in and around the city of Derby, UK showed a 5 to 6 fold increase in the absolute numbers 1 
of adults diagnosed between 1990 and 2006, not dissimilar to our own reported relative increase in 2 
incidence rates
35 36
.  Equally, an estimated prevalence from this area at the end of 1999 was around 3 
0.14%
24
 and was similar to our estimate for 1999 of 0.11%.   Second, a small study of CD incidence in 4 
East Dorset, UK, found an increase from 6.0  ? 13.3 per 100,000, 1993  ? 2002, which was also similar 5 
to our national estimates.
18
 In contrast the third study from USA showed a plateau of diagnosis rates 6 
in the last 6 years of their study (2004-2010) potentially indicating a ceiling to CD case finding 7 
through clinical presentation.  8 
 Other studies have reported incidence in adults but these are mostly from periods prior to the 9 
beginning of our study period or among selected populations therefore hindering valid comparisons.  10 
In the US for example among military personnel a low rate of 3.5 per 100,000 was observed and 11 
between 1999 and 2008 the rates increased 5 to 10 fold but this occupational population was 12 
relatively young and considered reasonably healthy by the authors
17
.   13 
For DH the most comprehensive study is that from Finland by Salmi et al which measured incidence 14 
over a 30 year period (following an original report in 2007
21
) and elegantly summarised the existing 15 
literature prior to its publication
22
.  They observed an overall annual incidence rate among children 16 
and adults which decreased substantially over the period of the study from 5.2 to 2.7 per 100,000, 17 
1970 - 2009.  Our rates were lower but showed a similar rate of decline.  Previous prevalence 18 
estimates from the 1970s
22
 onwards in Europe and the USA range from 10 per 100,000 or 0.01% to 19 
75 per 100,000 in the Finnish study or 0.075%, a range that includes our own overall estimate of 20 
0.03%. 21 
Though we believe that the close correlation of our results with previous data, as well as the 22 
robustness of our methodology should reassure that our results are correct, there are two major 23 
findings that need to be further explained. These are firstly the marked regional and socioeconomic 24 
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variations in CD but not DH, and secondly the contrasting rise in CD while DH fell.  Our findings of 1 
considerable regional and socioeconomic variation in incidence rates may indicate either that there is 2 
true variation in incidence or that ascertainment of disease varies. The lowest regional incidence was 3 
seen in London and a true variation in incidence by population characteristics such as ethnicity and 4 
mobility may be a contributing factor to this lower observed incidence
34 37
.   However we believe that 5 
it is more plausible that these observed variations in incidence are mediated through disparities in 6 
health seeking behaviour and access to correct diagnostic pathways.  Partly this is because in the 7 
more stable, less ethnically diverse populations of the UK where data on seroprevalence of 8 
undetected CD is available, i.e. Cambridge
38
, Bristol
39
 and Northern Ireland
40
, this is almost identical 9 
at about 1% yet the respective regional CD incidence rates in our study were 12, 15 and 22 per 10 
100,000, covering almost the entire range of regional incidence rates we report. These 11 
seroprevalence studies 
38-40
also report very little variation in undetected CD prevalence in the UK by 12 
age and sex suggesting that indeed health care utilisation is the most likely reason for the lower 13 
diagnosis rates in men and in certain age groups that we observed.  This interpretation is also likely 14 
to be generalizable to other health care systems in other countries as similar disparities have been 15 
observed in Olmsted County, Minnesota
4 41
 and the whole of Finland
42 43
, between clinically 16 
diagnosed incidence and prevalence estimates and seroprevalence studies. 17 
Thus the most logical explanation for the significant increase in incidence of CD over time is that 18 
there has been a substantial improvement in the diagnostic ascertainment of CD over the period 19 
studied.  For DH the same logic can be applied except for this disease we would have to hypothesize 20 
that diagnostic ascertainment has become worse over time to explain the decline.  Given that DH is a 21 
visible, itchy, blistering condition of extensor surfaces of the skin
44
 it seems highly unlikely that the 22 
reduction in incidence we, and others, have observed is related to a poorer pick up rate, so we 23 
believe the observed reduction is a true one.  By contrast the mechanisms by which CD is identified 24 
and diagnosed have changed and improved over our study period with the introduction of routinely 25 
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available serological tests, rapid and improved access to endoscopic services and greater awareness 1 
among patients and doctors.  Therefore the likelihood is that for CD greater ascertainment, rather 2 
than a true increase in incidence, explains our results.  Of course if ascertainment is increased when 3 
the pool of clinical disease itself is not, the observed increase in incidence would most likely occur 4 
through an increase in the diagnosis of milder or earlier cases.  This leads to the speculation that the 5 
relationship between the trends over time for CD and DH were not independent as proposed by 6 
Salmi et al
22
. If we consider DH to be a consequence of untreated CD per se then by identifying and 7 
treating earlier and milder CD we may be preventing the skin manifestations from presenting.  This is 8 
in effect proposing at an individual level, the hypothesis previously proposed at a population level to 9 
explain the decline in DH in Finland where gluten consumption has declined nationally
22 45
.  However, 10 
such a hypothesis requires far more evidence before it could be considered a causal explanation. 11 
In conclusion, we have provided contemporary, population based, precise estimates of the incidence 12 
and prevalence of both CD and DH in the UK over a 22 year period.  We have quantified the likely 13 
burden of this disease on health care systems and society in general.  We have shown that the 14 
incidence of CD has risen markedly during the period of our study and that, by contrast, DH incidence 15 
has fallen.  The highest incidence of CD was seen among the very young and over 50s whereas a 16 
steadily higher incidence with increasing age was seen for DH.  Twice as many women as men get 17 
diagnosed with CD and incidence rates vary regionally and by socioeconomic area.  These findings 18 
raise the possibility that inequality in the diagnostic pathways across time, place and person exist in 19 
the UK given that it is thought that most sections of society appear to have a reasonably similar 20 
background risk of having CD.   21 
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Table 1: Incidence of coeliac disease 1 
(Exact/each year was included in the Poisson model as categorical, as there was a significant 2 
departure from linear trend (Likelihood ratio test p=0.0001)) 3 
 Cases Person years 
Incidence rate (per 100,000 
person years) [95% CI] 
Incidence rate 
ratio*[95% CI] 
All 9087 65856848 13.80 [13.52, 14.08]  
Sex       
Male 3137 32679920 9.60 [9.27, 9.94] 1.00 (ref) 
Female 5950 33176929 17.93 [17.48, 18.40] 1.85 [1.78,1.94] 
Age group . . . . .  
<5 390 2550088 15.29 [13.81, 16.89] 1.00 (ref) 
5-17 929 10140413 9.16 [8.58, 9.77] 0.59 [0.52,0.66] 
18-29 809 8922980 9.07 [8.45, 9.71] 0.59 [0.53,0.67] 
30-49 2768 19716119 14.04 [13.52, 14.57] 0.91 [0.82,1.01] 
50-69 2916 16041746 18.18 [17.52, 18.85] 1.15 [1.03,1.28] 
70+ 1275 8485502 15.03 [14.21, 15.87] 0.91 [0.82,1.02] 
Year . . . . .  
1990 51 988225 5.16 [3.84, 6.79] 1.00 (ref) 
1991 95 968428 9.81 [7.94, 11.99] 1.84 [1.31,2.58] 
1992 75 1145736 6.55 [5.15, 8.21] 1.23 [0.86,1.75] 
1993 84 1302251 6.45 [5.15, 7.99] 1.22 [0.86,1.72] 
1994 93 1402018 6.63 [5.35, 8.13] 1.25 [0.89,1.76] 
1995 117 1502788 7.79 [6.44, 9.33] 1.46 [1.05,2.03] 
1996 137 1707438 8.02 [6.74, 9.49] 1.50 [1.09,2.07] 
1997 155 2037465 7.61 [6.46, 8.90] 1.42 [1.03,1.95] 
1998 241 2320549 10.39 [9.12, 11.78] 1.93 [1.43,2.62] 
1999 322 2732415 11.78 [10.53, 13.14] 2.19 [1.63,2.94] 
2000 367 3230521 11.36 [10.23, 12.58] 2.11 [1.58,2.83] 
2001 422 3522256 11.98 [10.86, 13.18] 2.23 [1.66,2.98] 
2002 485 3773659 12.85 [11.73, 14.05] 2.38 [1.79,3.18] 
2003 578 3927535 14.72 [13.54, 15.97] 2.72 [2.04,3.62] 
2004 504 4066850 12.39 [11.33, 13.52] 2.29 [1.72,3.06] 
2005 617 4184895 14.74 [13.60, 15.95] 2.73 [2.05,3.63] 
2006 636 4228443 15.04 [13.89, 16.26] 2.78 [2.09,3.70] 
2007 673 4270604 15.76 [14.59, 17.00] 2.92 [2.20,3.88] 
2008 768 4269975 17.99 [16.74, 19.30] 3.34 [2.51,4.43] 
2009 722 4282448 16.86 [15.65, 18.14] 3.13 [2.36,4.16] 
2010 808 4218998 19.15 [17.85, 20.52] 3.56 [2.68,4.73] 
2011 790 4127638 19.14 [17.83, 20.52] 3.55 [2.68,4.72] 
Region       
North East 146 1355821 10.77 [9.09, 12.66] 1.00 (ref) 
North West 1121 8425342 13.31 [12.54, 14.11] 1.18 [0.99,1.40] 
Yorkshire & The 
Humber 383 2993984 12.79 [11.54, 14.14] 
1.22 [1.01,1.48] 
East Midlands 396 2758331 14.36 [12.98, 15.84] 1.36 [1.12,1.64] 
West Midlands 796 5786860 13.76 [12.82, 14.75] 1.21 [1.01,1.45] 
East of England 799 6441340 12.40 [11.56, 13.30] 1.08 [0.90,1.29] 
South West 778 4994795 15.58 [14.50, 16.71] 1.30 [1.08,1.55] 
South Central 1035 7061717 14.66 [13.78, 15.58] 1.15 [0.97,1.38] 
London 715 7183686 9.95 [9.24, 10.71] 0.85 [0.71,1.02] 
South East Coast 777 5613311 13.84 [12.89, 14.85] 1.14 [0.95,1.36] 
Northern Ireland 510 2292558 22.25 [20.36, 24.26] 1.88 [1.56,2.27] 
Scotland 887 5253856 16.88 [15.79, 18.03] 1.36 [1.14,1.62] 
Wales 744 5695248 13.06 [12.14, 14.04] 1.11 [0.93,1.32] 
SES Quintile 
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1 ( Least deprived) 1909 12297158 15.52 [14.84, 16.24] 1.00 (ref) 
2 1841 12531110 14.69 [14.03, 15.38] 0.97 [0.91,1.04] 
3 1788 12874502 13.89 [13.25, 14.55] 0.92 [0.86,0.98] 
4 1978 14983975 13.20 [12.63, 13.80] 0.89 [0.84,0.95] 
5 (Most deprived) 1571 13170103 11.93 [11.35, 12.53] 0.83 [0.77,0.89] 
*adjusted for all other variables in the table 1 
 2 
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Table 2: Incidence of dermatitis herpetiformis 1 
(Year was included in the model as a continuous variable, as there was no significant departure from 2 
a linear trend (Likelihood ratio test p=0.1886)) 3 
 Cases Person 
years 
Incidence rate (per 
100,000 person years) 
[95% CI] 
Incidence rate 
ratio*[95% CI] 
All  809 65856848 1.23 [1.15, 1.32]  
Sex 
. . . . .  
Male 395 32679920 1.21 [1.09, 1.33] 1.00 (ref) 
Female 414 33176929 1.25 [1.13, 1.37] 0.99 [0.87,1.14] 
Age group 
. . . . .  
<5 18 2550088 0.71 [0.42, 1.12] 1.00 (ref) 
5-17 47 10140413 0.46 [0.34, 0.62] 0.66 [0.39,1.14] 
18-29 61 8922980 0.68 [0.52, 0.88] 0.97 [0.57,1.64] 
30-49 223 19716119 1.13 [0.99, 1.29] 1.61 [0.99,2.59] 
50-69 311 16041746 1.94 [1.73, 2.17] 2.78 [1.73,4.48] 
>69 149 8485502 1.76 [1.49, 2.06] 2.51 [1.54,4.10] 
Year 
. . . . .  
1990 18 988225 1.82 [1.08, 2.88] 0.96 [0.94,0.97]** 
1991 24 968428 2.48 [1.59, 3.69]  
1992 26 1145736 2.27 [1.48, 3.33]  
1993 21 1302251 1.61 [1.00, 2.47]  
1994 20 1402018 1.43 [0.87, 2.20]  
1995 21 1502788 1.40 [0.87, 2.14]  
1996 29 1707438 1.70 [1.14, 2.44]  
1997 30 2037465 1.47 [0.99, 2.10]  
1998 35 2320549 1.51 [1.05, 2.10]  
1999 47 2732415 1.72 [1.26, 2.29]  
2000 49 3230521 1.52 [1.12, 2.01]  
2001 48 3522256 1.36 [1.00, 1.81]  
2002 52 3773659 1.38 [1.03, 1.81]  
2003 52 3927535 1.32 [0.99, 1.74]  
2004 26 4066850 0.64 [0.42, 0.94]  
2005 50 4184895 1.19 [0.89, 1.58]  
2006 56 4228443 1.32 [1.00, 1.72]  
2007 44 4270604 1.03 [0.75, 1.38]  
2008 43 4269975 1.01 [0.73, 1.36]  
2009 45 4282448 1.05 [0.77, 1.41]  
2010 33 4218998 0.78 [0.54, 1.10]  
2011 33 4127638 0.80 [0.55, 1.12]  
Region 
. . . . .  
North East 8 1355821 0.59 [0.25, 1.16] 1.00 (ref) 
North West 108 8425342 1.28 [1.05, 1.55] 2.15 [1.05,4.42] 
Yorkshire & The 
Humber 64 2993984 2.14 [1.65, 2.73] 
3.37 [1.61,7.05] 
East Midlands 36 2758331 1.31 [0.91, 1.81] 2.03 [0.94,4.38] 
West Midlands 71 5786860 1.23 [0.96, 1.55] 2.07 [1.00,4.31] 
East of England 74 6441340 1.15 [0.90, 1.44] 1.84 [0.88,3.84] 
South West 52 4994795 1.04 [0.78, 1.37] 1.69 [0.80,3.58] 
South Central 89 7061717 1.26 [1.01, 1.55] 2.22 [1.07,4.61] 
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London 75 7183686 1.04 [0.82, 1.31] 1.86 [0.89,3.87] 
South East Coast 62 5613311 1.10 [0.85, 1.42] 1.88 [0.89,3.94] 
Northern Ireland 27 2292558 1.18 [0.78, 1.71] 2.18 [0.98,4.81] 
Scotland 72 5253856 1.37 [1.07, 1.73] 2.50 [1.20,5.20] 
Wales 71 5695248 1.25 [0.97, 1.57] 2.12 [1.02,4.41] 
SES quintile 
      
1 153 12297158 1.24 [1.05, 1.46] 1.00 (ref) 
2 144 12531110 1.15 [0.97, 1.35] 0.93 [0.74,1.17] 
3 180 12874502 1.40 [1.20, 1.62] 1.15 [0.92,1.44] 
4 164 14983975 1.09 [0.93, 1.28] 0.86 [0.69,1.09] 
5 168 13170103 1.28 [1.09, 1.48] 1.01 [0.81,1.27] 
*adjusted for all other variables in the table ** model fitted a linear trend.  IRR = one year increase in calendar time. 1 
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 1 
 2 
Figure 1: 3-year rolling average incidence of coeliac disease, 1990-2011, by age group 3 
 4 
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 1 
Figure 2: Map of incidence of coeliac disease by regional government office 2 
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 1 
 2 
Figure 3: 3-year rolling average incidence rates of dermatitis herpetiformis, 1990-2011, by age group 3 
 4 
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 1 
Figure 4: Map of incidence of dermatitis herpetiformis by regional government office 2 
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Table 3: Point prevalence of coeliac disease and dermatitis herpetiformis, 30 June 2011 1 
 Coeliac 
Disease 
(n) 
Prevalence 
(%) 
95% CI Dermatitis 
Herpetiformis 
(n) 
Prevalence 
(%) 
95% CI 
Overall 10872 0.24 [0.24,0.25] 1160 0.03 [0.02,0.03] 
Sex . . . . . . 
Male 3662 0.16 [0.16,0.17] 560 0.03 [0.02,0.03] 
Female 7210 0.32 [0.31,0.32] 600 0.03 [0.02,0.03] 
Age group . . . . . . 
<5 93 0.03 [0.03,0.04] 7 0.00 [0.00,0.00] 
5-17 903 0.13 [0.13,0.14] 38 0.01 [0.00,0.01] 
18-29 1026 0.15 [0.14,0.16] 64 0.01 [0.01,0.01] 
30-49 2952 0.23 [0.22,0.24] 245 0.02 [0.02,0.02] 
50-69 3948 0.37 [0.36,0.38] 491 0.05 [0.04,0.05] 
70+ 1950 0.38 [0.36,0.40] 315 0.06 [0.05,0.07] 
Region . . . . . . 
North East 171 0.22 [0.18,0.25] 22 0.03 [0.02,0.04] 
North West 1267 0.24 [0.22,0.25] 121 0.02 [0.02,0.03] 
Yorkshire & The 
Humber 
276 0.26 [0.23,0.30] 47 0.04 [0.03,0.06] 
East Midlands 226 0.28 [0.24,0.32] 23 0.03 [0.02,0.04] 
West Midlands 944 0.25 [0.23,0.27] 91 0.02 [0.02,0.03] 
East of England 819 0.23 [0.22,0.25] 86 0.02 [0.02,0.03] 
South West 1072 0.28 [0.26,0.30] 106 0.03 [0.02,0.03] 
South Central 1408 0.25 [0.24,0.26] 148 0.03 [0.02,0.03] 
London 905 0.16 [0.15,0.17] 87 0.02 [0.01,0.02] 
South East Coast 1019 0.23 [0.22,0.25] 82 0.02 [0.01,0.02] 
Northern Ireland 592 0.39 [0.36,0.42] 67 0.04 [0.03,0.06] 
Scotland 1203 0.27 [0.26,0.29] 166 0.04 [0.03,0.04] 
Wales 970 0.22 [0.21,0.24] 114 0.03 [0.02,0.03] 
 2 
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1 
Figure 5: Incidence of coeliac disease (CD) overall, and when the definition is restricted to either 2 2 
diagnostic codes or a gluten free prescription. 3 
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 1 
Figure 6: Incidence of dermatitis herpetiformis (DH) overall, the restricted definition to either 2 2 
diagnostic codes or a dapsone or gluten free prescription, and the broader definition including 3 
coeliac disease patients with a prescription for dapsone. 4 
 5 
6 
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